Eruptive squamous cell carcinoma in a patient receiving abatacept for rheumatoid arthritis

Journal of the American Academy of Dermatology

Volumn 69, Issue 4, 2013, Pages

  Corcorran, Maria A ^a   Olson, Jonathan M ^a,b   Hecht, Corinne ^a,b   Knezevich, Stevan ^b,c   Vary, Jay C ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; FLUOROURACIL;

ACTINIC KERATOSIS; ADULT; CASE REPORT; CRYOTHERAPY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HYPERKERATOSIS; LETTER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 84884341798     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.04.018     Document Type: Article

References (5)

1. E.F. Chakravarty, K. Michaud, and F. Wolfe Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors J Rheumatol 32 2005 2130 2135
2. J.L. DePry, K.B. Reed, R.H. Cook-Norris, and J.D. Brewer Iatrogenic immunosuppression and cutaneous malignancy Clin Dermatol 29 2011 602 613
3. L.J. Maxwell, and J.A. Singh Abatacept for rheumatoid arthritis: a Cochrane systematic review J Rheumatol 37 2010 234 245
4. J.M. Kremer, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, and R. Westhovens Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial Ann Rheum Dis 70 2011 1826 1830
5. M. Lebwohl, R. Blum, E. Berkowitz, D. Kim, R. Zitnik, and C. Osteen No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years Arch Dermatol 141 2005 861 864